Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 long-term extension in essential hypertension
NCT01256411Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of sacubitril + valsartan in essential hypertension, sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events, Serious Adverse Events, and Deaths at 12 months. Started Nov 2010; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01256411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01256411.